Clinical Trial Update: CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML [Phase 4]

View source ↗

Summary

This Phase 4 trial compares CLAG+venetoclax versus CLAG for relapsed/refractory acute myeloid leukemia and is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CLAG
• Venetoclax (venetoclax)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Relapsed/Refractory AML | Phase 4 | Status: NOT_YET_RECRUITING